课题基金 / 基金详情

Novel role for adiponectin-enhancing drugs for asthma in the obese

Novel role for adiponectin-enhancing drugs for asthma in the obese
脂联素增强药物治疗肥胖哮喘的新作用
批准号:
8726688
负责人:
AKSHAY SOOD
金额:
$39.51万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2017-01-31

项目摘要

项目成果

AKSHAY SOOD的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):哮喘是一种慢性肺部疾病,影响8.2%的美国成年人,特别是肥胖者。目前哮喘的治疗主要涉及吸入皮质类固醇,但这些药物在肥胖个体中效果较差。因此,发现针对肥胖个体的更有效的哮喘药物存在未满足的需求。最近的研究表明,血清脂联素(脂肪组织的独特抗炎产物)浓度低,可预测某些人群中哮喘的发生和更严重的哮喘临床严重程度。此外,低脂联素与抑郁症和缺血性心血管疾病相关。有效的脂联素增强药物包括抗糖尿病药物类噻唑烷二酮类(TZD)和抗高血压药物类血管紧张素受体阻滞剂(ARB)。我们的总体假设是,在肥胖的成年人中使用脂联素增强药物可以帮助预防或治疗哮喘、抑郁症和缺血性心血管疾病。具体目标1:在伴有糖尿病和/或高血压的肥胖受试者中,确定脂联素增强药物对哮喘、抑郁症或缺血性心血管疾病的影响。基于我们的初步数据,我们的工作主要假设是TZD和/或ARB的使用与发生哮喘的风险低于其他抗糖尿病和/或抗高血压药物的使用相关,并且这种相关性在女性中比男性更强。我们的次要假设是,在这一人群中,抑郁症和缺血性心血管疾病的发生也有类似的有益效果。这项拟议中的研究使用退伍军人管理局(VA)国家数据系统,对20多年来的美国退伍军人进行了纵向队列研究。我们将对每种疾病进行平行分析,首先在“基线”访视时排除流行疾病,然后在后续访视时分析偶发疾病。具体目标二:确定脂联素增强药物对患有该疾病(即哮喘、抑郁症或缺血性心血管疾病)+肥胖症+伴随糖尿病和/或高血压的受试者的疾病并发症风险的影响。基于我们的初步数据,我们的工作主要假设是,在我们的哮喘人群亚组中,TZD和/或ARB的使用与哮喘急性发作的风险低于其他抗糖尿病和/或抗高血压药物的使用相关,并且这种相关性在女性中比男性更强。我们的次要假设是,类似的有益效果被视为与急诊室访问或住院抑郁症或缺血性心血管疾病。对于特定目标2,我们将仅在每个统计模型中纳入流行疾病,并分析与该疾病相关的并发症风险。生存分析将用于研究目标1和2中的事件。如果我们的研究表明,脂联素增强药物有利地影响与低脂联素血症相关的疾病的自然史,这将有助于开发预防和治疗肥胖者哮喘、抑郁症和缺血性心血管疾病的新策略。
英文摘要
DESCRIPTION (provided by applicant): Asthma is a chronic lung disease that affects 8.2% of all American adults, particularly obese individuals. Current treatment for asthma primarily involves inhaled corticosteroids but these drugs are less effective among obese individuals. There is therefore an unmet need to discover more efficacious asthma medications targeting obese individuals. Recent research has shown that low serum concentrations of adiponectin, a unique anti-inflammatory product of adipose tissue, predict both incident asthma and worse clinical severity of asthma in some populations. In addition, low adiponectin is similarly associated with depression and ischemic cardiovascular disease. Potent adiponectin-enhancing drugs include the antidiabetic drug class of thiazolidinediones (TZD) and antihypertensive drug class of angiotensin receptor blockers (ARB). Our overarching hypothesis is that use of adiponectin-enhancing drugs among obese adults can help prevent or treat asthma as well as depression and ischemic cardiovascular disease. Specific Aim 1: To determine the effect of adiponectin-enhancing drugs on incident asthma, depression or ischemic cardiovascular disease among obese subjects with concomitant diabetes and/or hypertension. Based upon our preliminary data, our working primary hypothesis is that TZD and/or ARB use is associated with a lower risk for developing incident asthma than use of other antidiabetic and/or antihypertensive drugs and this association is stronger among women than men. Our secondary hypotheses are that similar beneficial effects are seen with respect to incident depression and incident ischemic cardiovascular disease in this population. The proposed study examines a longitudinal cohort of veteran Americans over two decades, using the Veterans Administration (VA) National Data System. We will conduct parallel analyses for each disease in which we first exclude prevalent disease at 'baseline' visit and analyze incident disease at subsequent visits. Specific Aim 2: To determine the effect of adiponectin-enhancing drugs on risk for disease complications among subjects with that disease (i.e. asthma, depression or ischemic cardiovascular disease) plus obesity plus concomitant diabetes and/or hypertension. Based upon our preliminary data, our working primary hypothesis is that TZD and/or ARB use in our population subgroup with asthma is associated with a lower risk for asthma exacerbations than use of other antidiabetic and/or antihypertensive drugs and this association is stronger among women than men. Our secondary hypotheses are that similar beneficial effects are seen with respect to emergency room visits or hospitalizations from depression or ischemic cardiovascular disease. For Specific Aim 2, we will include only those with prevalent disease in each statistical model and analyze risk for complications related to that disease. Survival analysis will be used to study the events in Aims 1 and 2. If our research shows that adiponectin-enhancing drugs favorably affect the natural history of diseases related to hypoadiponectinemia, it will help develop novel strategies for preventing and treating asthma as well as depression and ischemic cardiovascular disease in the obese.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Effectiveness of Innovative Research Mentor Interventions among Underrepresented Minority Faculty in the Southwest
Effectiveness of Innovative Research Mentor Interventions among Underrepresented Minority Faculty in the Southwest
国内基金
海外基金
水稻根长与抗旱基因RoLe1的克隆与分子机制解析
  • 批准号:
    32401809
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2024
  • 负责人:
    李颖秀
  • 依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
  • 批准号:
    82371070
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵培泉
  • 依托单位: